Current management of patients with melanoma who are found to be sentinel node-positive.

ABSTRACT:

Background

The results of the DeCOG-SLT and MSLT-II studies, published in 2016 and mid-2017, indicated no survival benefit from completion lymph node dissection (CLND) in melanoma patients with positive sentinel nodes (SNs). Subsequently, several studies have been published reporting a benefit of adjuvant systemic therapy in patients with stage III melanoma. The current study assessed how these findings influenced management of SN-positive patients in a dedicated melanoma treatment centre.

Methods

SN-positive patients treated at Melanoma Institute Australia between July 2017 and December 2018 were prospectively identified. Surgeons completed a questionnaire documenting the management of each patient. Information on patients, primary tumours, SNs, further treatment and follow

SUBMITTER: Nijhuis AAG 

PROVIDER: S-EPMC7216885 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature